NDAORALCAPSULE, DELAYED RELEASE
Approved
Jul 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
DORYX (doxycycline hyclate) by Pfizer is tetracycline-class antimicrobial drug [ see ]. Approved for gonorrhea, chlamydia, syphilis and 3 more indications. First approved in 1985.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DORYX is an oral delayed-release doxycycline hyclate capsule, a tetracycline-class antimicrobial approved in 1985. It treats sexually transmitted infections (gonorrhea, chlamydia, syphilis), acne vulgaris, H. pylori infection, and mucositis by inhibiting bacterial protein synthesis. The delayed-release formulation aims to improve tolerability and reduce GI side effects associated with immediate-release doxycycline.
$0.018BPart D
LOE ApproachingLimited commercial growth expected as LOE approaches; brand team likely focused on defensive positioning and lifecycle management rather than expansion.
Mechanism of Action
tetracycline-class antimicrobial drug [ see ].
Indications (6)
Worked on DORYX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.